Activin Signaling As an Emerging Target for Therapeutic Interventions

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2009 Jun 23

PMID 19538713

Citations 81

Authors

Kunihiro Tsuchida

Masashi Nakatani

Keisuke Hitachi

Akiyoshi Uezumi

Yoshihide Sunada

Hiroshi Ageta

Kaoru Inokuchi

Affiliations

Soon will be listed here.

Abstract

After the initial discovery of activins as important regulators of reproduction, novel and diverse roles have been unraveled for them. Activins are expressed in various tissues and have a broad range of activities including the regulation of gonadal function, hormonal homeostasis, growth and differentiation of musculoskeletal tissues, regulation of growth and metastasis of cancer cells, proliferation and differentiation of embryonic stem cells, and even higher brain functions. Activins signal through a combination of type I and II transmembrane serine/threonine kinase receptors. Activin receptors are shared by multiple transforming growth factor-beta (TGF-beta) ligands such as myostatin, growth and differentiation factor-11 and nodal. Thus, although the activity of each ligand is distinct, they are also redundant, both physiologically and pathologically in vivo. Activin receptors activated by ligands phosphorylate the receptor-regulated Smads for TGF-beta, Smad2 and 3. The Smad proteins then undergo multimerization with the co-mediator Smad4, and translocate into the nucleus to regulate the transcription of target genes in cooperation with nuclear cofactors. Signaling through receptors and Smads is controlled by multiple mechanisms including phosphorylation and other posttranslational modifications such as sumoylation, which affect potein localization, stability and transcriptional activity. Non-Smad signaling also plays an important role in activin signaling. Extracellularly, follistatin and related proteins bind to activins and related TGF-beta ligands, and control the signaling and availability of ligands.The functions of activins through activin receptors are pleiotrophic, cell type-specific and contextual, and they are involved in the etiology and pathogenesis of a variety of diseases. Accordingly, activin signaling may be a target for therapeutic interventions. In this review, we summarize the current knowledge on activin signaling and discuss the potential roles of this pathway as a molecular target of therapy for metabolic diseases, musculoskeletal disorders, cancers and neural damages.

Citing Articles

Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner.

Wiley M, Bauer J, Alvarez V, Kolics Z, Cheng W, Church D Sci Rep. 2025; 15(1):8509.

PMID: 40075112 PMC: 11903883. DOI: 10.1038/s41598-025-91853-9.

Diversity of Microglia-Derived Molecules with Neurotrophic Properties That Support Neurons in the Central Nervous System and Other Tissues.

Wiens K, Wasti N, Ulloa O, Klegeris A Molecules. 2024; 29(23).

PMID: 39683685 PMC: 11643984. DOI: 10.3390/molecules29235525.

Smad transcription factors as mediators of 7 transmembrane G protein-coupled receptor signalling.

Chia Z, Kumarapperuma H, Zhang R, Little P, Kamato D Acta Pharmacol Sin. 2024; .

PMID: 39506064 DOI: 10.1038/s41401-024-01413-6.

Multi-Omic Analysis Reveals Genetic Determinants and Therapeutic Targets of Chronic Kidney Disease and Kidney Function.

Lu Y, Wang Y Int J Mol Sci. 2024; 25(11).

PMID: 38892221 PMC: 11172763. DOI: 10.3390/ijms25116033.

Increase in activin A may counteract decline in synaptic plasticity with age.

Zheng F, Dahlmanns M, Kessler P, Alzheimer C Front Aging Neurosci. 2024; 16:1382492.

PMID: 38646448 PMC: 11026702. DOI: 10.3389/fnagi.2024.1382492.

References

Rodino-Klapac L, Haidet A, Kota J, Handy C, Kaspar B, Mendell J . Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009; 39(3):283-96. PMC: 2717722. DOI: 10.1002/mus.21244. View

Oxburgh L, Chu G, Michael S, Robertson E . TGFbeta superfamily signals are required for morphogenesis of the kidney mesenchyme progenitor population. Development. 2004; 131(18):4593-605. DOI: 10.1242/dev.01324. View

Frandsen U, Porneki A, Floridon C, Abdallah B, Kassem M . Activin B mediated induction of Pdx1 in human embryonic stem cell derived embryoid bodies. Biochem Biophys Res Commun. 2007; 362(3):568-74. DOI: 10.1016/j.bbrc.2007.07.200. View

Colussi C, Gaetano C, Capogrossi M . AAV-dependent targeting of myostatin function: follistatin strikes back at muscular dystrophy. Gene Ther. 2008; 15(15):1075-6. DOI: 10.1038/gt.2008.95. View

Asashima M, Michiue T, Kurisaki A . Elucidation of the role of activin in organogenesis using a multiple organ induction system with amphibian and mouse undifferentiated cells in vitro. Dev Growth Differ. 2008; 50 Suppl 1:S35-45. DOI: 10.1111/j.1440-169X.2008.00990.x. View

Halder S, Beauchamp R, Datta P . A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005; 7(5):509-21. PMC: 1501161. DOI: 10.1593/neo.04640. View

Foster J, Puchowicz M, McIntyre D, Herkenham M . Activin mRNA induced during amygdala kindling shows a spatiotemporal progression that tracks the spread of seizures. J Comp Neurol. 2004; 476(1):91-102. DOI: 10.1002/cne.20197. View

Minetti G, Colussi C, Adami R, Serra C, Mozzetta C, Parente V . Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006; 12(10):1147-50. DOI: 10.1038/nm1479. View

Hjelmeland M, Hjelmeland A, Sathornsumetee S, Reese E, Herbstreith M, Laping N . SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004; 3(6):737-45. View

10.

Trudeau V, Theodosis D, Poulain D . Activin facilitates neuronal development in the rat amygdala. Neurosci Lett. 1997; 237(1):33-6. DOI: 10.1016/s0304-3940(97)00796-9. View

11.

McPherron A, Lawler A, Lee S . Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997; 387(6628):83-90. DOI: 10.1038/387083a0. View

12.

Kurisaki A, Inoue I, Kurisaki K, Yamakawa N, Tsuchida K, Sugino H . Activin induces long-lasting N-methyl-D-aspartate receptor activation via scaffolding PDZ protein activin receptor interacting protein 1. Neuroscience. 2008; 151(4):1225-35. DOI: 10.1016/j.neuroscience.2007.12.012. View

13.

Kang J, Saunier E, Akhurst R, Derynck R . The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol. 2008; 10(6):654-64. PMC: 2649123. DOI: 10.1038/ncb1728. View

14.

Kogame M, Matsuo S, Nakatani M, Kurisaki A, Nishitani H, Tsuchida K . ALK7 is a novel marker for adipocyte differentiation. J Med Invest. 2006; 53(3-4):238-45. DOI: 10.2152/jmi.53.238. View

15.

Matzuk M, Lu N, Vogel H, Sellheyer K, Roop D, Bradley A . Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995; 374(6520):360-3. DOI: 10.1038/374360a0. View

16.

Muller M, Zheng F, Werner S, Alzheimer C . Transgenic mice expressing dominant-negative activin receptor IB in forebrain neurons reveal novel functions of activin at glutamatergic synapses. J Biol Chem. 2006; 281(39):29076-84. DOI: 10.1074/jbc.M604959200. View

17.

Adkins H, Bianco C, Schiffer S, Rayhorn P, Zafari M, Cheung A . Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003; 112(4):575-87. PMC: 171388. DOI: 10.1172/JCI17788. View

18.

Shelton G, Engvall E . Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord. 2007; 17(9-10):721-2. DOI: 10.1016/j.nmd.2007.06.008. View

19.

Wagner K, McPherron A, Winik N, Lee S . Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002; 52(6):832-6. DOI: 10.1002/ana.10385. View

20.

Shen J, Huang L, Li L, Jorgez C, Matzuk M, Brown C . Deficiency of growth differentiation factor 3 protects against diet-induced obesity by selectively acting on white adipose. Mol Endocrinol. 2008; 23(1):113-23. PMC: 2646597. DOI: 10.1210/me.2007-0322. View